Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy

Journal of Hypertension

Volumn 23, Issue 11, 2005, Pages 1931-1937

  Leon, Carlos A ^a   Raij, Leopoldo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; End stage renal disease; Pathophysiology; Renal insufficiency

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE TRANSPORTER 1; HYDRALAZINE; IRBESARTAN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY METABOLISM; MESANGIUM; MICROALBUMINURIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 29244437170     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000188415.65040.5d     Document Type: Review

References (59)

1. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74:1184-1155.
2. Andersen AR, Christiansen PK, Andersen JK, Kreiner S, Decker T. Diabetic nephropathy in type 1 (insulin dependent) diabetes, an epidemiological study. Diabetologia 1983; 25:496-501.
3. United States Renal Data System. USRDS 2000 annual data report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases 2001; http://www.usrds.org/adr_2000.htm. [Accessed 18 March 2002]
4. European Dialysis and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant 1996; 11 (Suppl 7):1-32.
5. UK Prospective Diabetes Study (UKPDS). IX. Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months' diet therapy. Diabetologia 1993; 36:835-842.
6. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127-1133.
7. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44:1303-1309.
8. Tagle R, Acevedo M, Vidt DG. Microalbuminuria: is it a valid predictor of cardiovascular risk? Cleve Clin J Med 2003; 70:255-261.
9. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 1994; 46:396-404.
10. Tolins JP, Raij L. Concerns about diabetic nephropathy in the treatment of diabetic hypertensive patients. Am J Med 1989; 87:29S-33S.
11. Keven K, Ekmekci Y. Opposing mechanisms in tubuloglomerular feedback. Am J Kidney Dis 2004; 44:574.
12. Raij L, Azar S, Keane WF. Role of hypertension in progressive glomerular immune injury. Hypertension 1985; 3:398-404.
13. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797-805.
14. Carmines PK, Ohishi K, Ikenaga H. Functional impairment of renal afferent arteriolar voltage-gated calcium channels in rats with diabetes mellitus. J Clin Invest 1996; 98:2564-2571.
15. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601-1608.
16. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346:1145-1151.
17. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 2001; 37:767-773.
18. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10(Suppl 12):S258-S265.
19. Lee LR, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995; 96:953-964.
20. Boffa J-J, Lu Y, Placier S, Stefanski A, Dussale J-C, Chatzi-Antoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14:1132-1144.
21. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24:366-378.
22. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68:S14-S19.
23. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004; 43:255-262.
24. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in genetic model of progressive nephropathy. Am J Kidney Dis 1999; 34:626-632.
25. Ikoma M, Kawamura T, Kakimura Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40:195-202.
26. Raij L. Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 2003; 16(11 Pt 2):46S-49S.
27. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961.
28. Osterby R. Glomerular structural changes in type 1 (insulin dependent) diabetes mellitus: causes, consequences and prevention. Diabetologia 1992; 35:803-812.
29. Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin dependent) diabetic patients. Diabetologia 1993; 36:1064-1070.
30. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38:1077-1081.
31. Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, Torffvit O. Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 2001; 109:751-761.
32. Osterby R, Hartman A, Nyengaard JR, Bangstad HJ. Development of renal structural lesions in type 1 diabetic patients with microalbuminuria. Observations by light microscopy in 8-year follow-up biopsies. Virchows Arch 2002; 440:94-101.
33. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26(Suppl 4):8-14.
34. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000; 11:1667-1673.
35. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187:251-259.
36. Risdon RA, Sloper JC, de Wardener HE. Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2 1968; 2:363-366.
37. Steffes MW, Bilous RW, Sutherland DER. Mauer SM. Cell and matrix components of the glomerular mesangium in type I diabetes mellitus. Diabetes 1992; 41:679-684.
38. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993; 43:661-667.
39. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93:536-542.
40. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease.The case of transforming growth factor β as a key mediator. Diabetes 1995; 44:1139-1146.
41. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000; 97:12222-12226.
42. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56:1627-1637.
43. +-coupled and facilitative transporters. Diabetologia 1995; 38:291-297.
44. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, et al. D-Glucose stimulates mesangial cell GLUT1 expression and basal and IGF-1-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 1997; 46:1030-1039.
45. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics mimics the diabetic phenotype. J Clin Invest 1995; 96:1802-1814.
46. Ewen ME, Sluss HK, Whitehouse LL, Livingstone DM. TGF-β inhibition of CDk4 synthesis is linked to cell cycle arrest. Cell 1993; 74:1009-1020.
47. Weigert C, Brodbeck K, Brocius FC III, Huber M, Lehman R, Friess U, et al. Evidence for a novel TGF-β1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 2003; 52:527-535.
48. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R. TGF-β1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 1999; 55:1704-1712.
49. Gnudi L, Viberti G, Raij L, Rodriguez V, Burt D, Cortes P, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003; 42:19-24.
50. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14:1816-1824.
51. Riser BL, Cortes P, Zhao X, Bernstein J, Dumier F, Narins RG. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992; 90:1932-1943.
52. Ziyadeh F, Sharma K. Combating diabetic nephropathy. J Am Soc Nephrol 2003; 14:1355-1357.
53. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, et al. Long term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expression by treatment with monoclonal anti TGF-β antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97:8015-8020.
54. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300:16-22.
55. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC, et al. Increased renal production of transforming growth factor beta 1 in patients with type II diabetes. Diabetes 1997; 46:854-859.
56. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 2002; 51:3577-3581.
57. Mason R, Abdel Wahab N. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14:1358-1373.
58. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.
59. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109:817-826.